Actelion Pharmaceuticals’ Tracleer (bosentan) increased the overall survival and reduced the hospitalizations of patients with pulmonary hypertension stemming from idiopathic pulmonary fibrosis, or IPF-PH, a Japanese clinical trial shows. Researchers published their preliminary findings on the ongoing long-term trial in the journal BMC Pulmonary Medicine. The title of the article…
Tracleer Increased Survival of Patients with Pulmonary Hypertension Due to IPF, Trial Shows
https://vimeo.com/162782590 In this photograph montage from Jason T. Beck called Celebrating Ricky Miller, we get a glimpse of the life of Ricky from Akron, Ohio, who battled idiopathic pulmonary fibrosis, a chronic condition that causes scarring in the lung tissue. MORE: Why we shouldn’t stop raising awareness…
Last week, I had my first appointment with the lung transplant team at the University of California, San Francisco (UCSF). Last month, I wrote a column about the team’s decision to meet with me. This first appointment went very well, better than expected! Praise God!…
Phelix Therapeutics has received a $201,665 National Institutes of Health (NIH) grant to continue studying Calpain-based treatments for tissue-scarring diseases like idiopathic pulmonary fibrosis and the liver condition nonalcoholic steatohepatitis. Doctors need better treatments for scarring — or fibrosis — diseases, Phelix said. Current therapies address some of the inflammation that occurs in these…
With increasing interest in natural remedies for the management of disease symptoms, discussion about the uses of essential oils flourishes. Advocates for oil companies, such as dōTERRA or Young Living, will tell you that there are “unlimited” benefits and uses for these oils to help you live…
Cells present in the outer rims of small blood vessels in the lung, called pericytes, convert from a healthy state into a fibrotic one, promoting the progression of pulmonary fibrosis, new findings suggest. The discovery shows how pericytes respond to the microenvironment in the lungs, especially the mechanical changes in…
Looking at pulmonary fibrosis (PF) as an age-related disease and working with a gene therapy that lengthens the life of lung cells, researchers report that they were able to lessen — and even stop — lung fibrosis in mice. “This is the first time that pulmonary fibrosis has been treated as an age-related disease, looking for rejuvenating the affected tissues,” Maria A. Blasco, study's lead author and group leader at the Spanish National Cancer Research Centre (CNIO), in Madrid, said in a press release. The study “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres” was published in the journal eLife.
There are a plethora of benefits for patients using online social media platforms. They help members of the community connect, and share and receive information about all aspects of the disease. Online social media platforms have a similar preface but do have differences in how and why they operate,…
Thinking back to my days of high school many years ago, I never imagined I would become involved with an online publication. I hated writing articles, papers, and essays, and I had little interest in research, chronic illness, or how words could be used to connect people so…
A pivotal Phase 3 trial evaluating PBI-4050, a potential treatment of idiopathic pulmonary fibrosis, will be open to all patients with mild-to-moderate IPF regardless of whether they are also taking Ofev (nintedanib) or not, the therapy’s developer, Prometic Life Sciences, announced. The trial, in other words, will evaluate the efficacy and safety of…
